Cargando…

Dual Targeting Ligands—Histamine H(3) Receptor Ligands with Monoamine Oxidase B Inhibitory Activity—In Vitro and In Vivo Evaluation

The clinical symptoms of Parkinson’s disease (PD) appear when dopamine (DA) concentrations in the striatum drops to around 20%. Simultaneous inhibitory effects on histamine H(3) receptor (H(3)R) and MAO B can increase DA levels in the brain. A series of compounds was designed and tested in vitro for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Łażewska, Dorota, Siwek, Agata, Olejarz-Maciej, Agnieszka, Doroz-Płonka, Agata, Wiktorowska-Owczarek, Anna, Jóźwiak-Bębenista, Marta, Reiner-Link, David, Frank, Annika, Sromek-Trzaskowska, Wioletta, Honkisz-Orzechowska, Ewelina, Królicka, Ewelina, Stark, Holger, Wieczorek, Marek, Wagner, Waldemar, Kieć-Kononowicz, Katarzyna, Stasiak, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607599/ https://www.ncbi.nlm.nih.gov/pubmed/36297622 http://dx.doi.org/10.3390/pharmaceutics14102187

Ejemplares similares

Multitargeting Histamine H(3) Receptor Ligands among Acetyl- and Propionyl-Phenoxyalkyl Derivatives
por: Łażewska, Dorota, et al.
Publicado: (2023)

Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H(3) Receptor Antagonists and Monoamine Oxidase B Inhibitors
por: Łażewska, Dorota, et al.
Publicado: (2020)

Chalcones as Potential Ligands for the Treatment of Parkinson’s Disease
por: Królicka, Ewelina, et al.
Publicado: (2022)

Anti-inflammatory effects of new human histamine H(3) receptor ligands with flavonoid structure on BV-2 neuroinflammation
por: Honkisz-Orzechowska, Ewelina, et al.
Publicado: (2022)

Biphenylalkoxyamine Derivatives–Histamine H(3) Receptor Ligands with Butyrylcholinesterase Inhibitory Activity
por: Łażewska, Dorota, et al.
Publicado: (2021)

Studies on Anticonvulsant Effects of Novel Histamine H3R Antagonists in Electrically and Chemically Induced Seizures in Rats
por: Alachkar, Alaa, et al.
Publicado: (2018)

Are the Hydantoin-1,3,5-triazine 5-HT(6)R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro
por: Lubelska, Annamaria, et al.
Publicado: (2019)

Trisubstituted 1,3,5-Triazines as Histamine H(4) Receptor Antagonists with Promising Activity In Vivo
por: Olejarz-Maciej, Agnieszka, et al.
Publicado: (2023)

Benzophenone Derivatives with Histamine H(3) Receptor Affinity and Cholinesterase Inhibitory Potency as Multitarget-Directed Ligands for Possible Therapy of Alzheimer’s Disease
por: Godyń, Justyna, et al.
Publicado: (2022)

New Triazine Derivatives as Serotonin 5-HT(6) Receptor Ligands
por: Łażewska, Dorota, et al.
Publicado: (2023)

Evaluation of Some Safety Parameters of Dual Histamine H(3) and Sigma-2 Receptor Ligands with Anti-Obesity Potential
por: Mika, Kamil, et al.
Publicado: (2023)

The Biological Activities of Cinnamon, Geranium and Lavender Essential Oils
por: Sienkiewicz, Monika, et al.
Publicado: (2014)

Anti-Inflammatory Activities of 8-Benzylaminoxanthines Showing High Adenosine A(2A) and Dual A(1)/A(2A) Receptor Affinity
por: Załuski, Michał, et al.
Publicado: (2023)

Diclofenac Diminished the Unfolded Protein Response (UPR) Induced by Tunicamycin in Human Endothelial Cells
por: Sokołowska, Paulina, et al.
Publicado: (2022)

The Importance of Endoplasmic Reticulum Stress as a Novel Antidepressant Drug Target and Its Potential Impact on CNS Disorders
por: Jóźwiak-Bębenista, Marta, et al.
Publicado: (2022)

Phenylalanine-Based AMPA Receptor Antagonist as the Anticonvulsant Agent with Neuroprotective Activity—In Vitro and In Vivo Studies
por: Latacz, Gniewomir, et al.
Publicado: (2022)

Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases
por: Załuski, Michał, et al.
Publicado: (2023)

Selenium-Containing Agents Acting on Cancer—A New Hope?
por: Garbo, Sabrina, et al.
Publicado: (2022)

Aryl-1,3,5-triazine ligands of histamine H(4) receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide
por: Mogilski, Szczepan, et al.
Publicado: (2016)

Novel GPR18 Ligands in Rodent Pharmacological Tests: Effects on Mood, Pain, and Eating Disorders
por: Frankowska, Małgorzata, et al.
Publicado: (2023)

The Histamine H3 Receptor Antagonist E159 Reverses Memory Deficits Induced by Dizocilpine in Passive Avoidance and Novel Object Recognition Paradigm in Rats
por: Alachkar, Alaa, et al.
Publicado: (2017)

Study on the effect of EMD386088, a 5-HT(6) receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats
por: Jastrzębska-Więsek, Magdalena, et al.
Publicado: (2017)

LC–MS–MS Method for the Analysis of New Non-Imidazole Histamine H(3) Receptor Antagonist 1-[3-(4-tert-Butylphenoxy)propyl]piperidine in Rat Serum—Application to Pharmacokinetic Studies
por: Szafarz, Malgorzata, et al.
Publicado: (2011)

The Structural Determinants for α(1)-Adrenergic/Serotonin Receptors Activity among Phenylpiperazine-Hydantoin Derivatives
por: Kucwaj-Brysz, Katarzyna, et al.
Publicado: (2021)

A Taxicab geometry quantification system to evaluate the performance of in silico methods: a case study on adenosine receptors ligands
por: Kuder, Kamil J., et al.
Publicado: (2020)

Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT(6) Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo
por: Kurczab, Rafał, et al.
Publicado: (2018)

Histamine H3 receptor antagonist E177 attenuates amnesia induced by dizocilpine without modulation of anxiety-like behaviors in rats
por: Alachkar, Alaa, et al.
Publicado: (2019)

Pharmaceutical and Safety Profile Evaluation of Novel Selenocompounds with Noteworthy Anticancer Activity
por: Marć, Małgorzata Anna, et al.
Publicado: (2022)

The Phenoxyalkyltriazine Antagonists for 5-HT(6) Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases
por: Sudoł, Sylwia, et al.
Publicado: (2021)

The role of PPARγ in TBBPA-mediated endocrine disrupting effects in human choriocarcinoma JEG-3 cells
por: Honkisz, Ewelina, et al.
Publicado: (2015)

Discovery of Potential, Dual-Active Histamine H(3) Receptor Ligands with Combined Antioxidant Properties
por: Kuder, Kamil J., et al.
Publicado: (2021)

Simultaneous Blockade of Histamine H(3) Receptors and Inhibition of Acetylcholine Esterase Alleviate Autistic-Like Behaviors in BTBR T+ tf/J Mouse Model of Autism
por: Eissa, Nermin, et al.
Publicado: (2020)

Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18
por: Neumann, Alexander, et al.
Publicado: (2020)

Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating
por: Kotańska, Magdalena, et al.
Publicado: (2021)

The Histamine H3 Receptor Antagonist DL77 Ameliorates MK801-Induced Memory Deficits in Rats
por: Eissa, Nermin, et al.
Publicado: (2018)

Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
por: Szumilak, Marta, et al.
Publicado: (2021)

The Neuroprotective Effects of Histamine H3 Receptor Antagonist E177 on Pilocarpine-Induced Status Epilepticus in Rats
por: Alachkar, Alaa, et al.
Publicado: (2019)

Neuroleptic Drugs and PACAP Differentially Affect the mRNA Expression of Genes Encoding PAC1/VPAC Type Receptors
por: Jóźwiak-Bębenista, Marta, et al.
Publicado: (2016)

Efficacy of the Multi-Target Compound E153 in Relieving Pain and Pruritus of Different Origins
por: Mogilski, Szczepan, et al.
Publicado: (2023)

Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α(2)-adrenoceptor and trace amine-associated receptor 1 ligand
por: Kotańska, Magdalena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_svt15dg6d462pavqi9b94h8hoh